Literature DB >> 19660682

Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment.

Marc C Chamberlain1, Michael Glantz, Morris D Groves, Wyndham H Wilson.   

Abstract

Three methods are routinely used to diagnose neoplastic meningitis (NM): clinical signs and symptoms, cerebrospinal fluid (CSF) cytology, and magnetic resonance imaging (MRI) of the brain and spine. Clinical manifestations are often subtle or may be ascribed to other cancer complications, eg, treatment-related disorders or brain parenchymal metastases. CSF cytology has a high specificity (>95%), but its sensitivity is generally less than 50%. MRI sensitivity and specificity vary with the type of primary cancer; overall, MRI findings consistent with leptomeningeal disease are detected in fewer than 50% of NM patients. While most clinicians evaluate CSF cytology along with MRI and the clinical examination, underdiagnosis is a major problem, since many patients are both cytologically and radiographically negative. Failure to consider NM in the differential diagnosis magnifies the problem of underdiagnosis. CSF flow cytometry is particularly promising for evaluating NM from hematologic cancers, with a diagnostic sensitivity many fold greater than conventional cytology. Research has focused on identifying biochemical markers of tumor cells in the CSF. For example, molecules involved in CNS penetration (eg, matrix metalloproteinases and cathepsins), tumor cell tropism (eg, chemokines CXCL8 and CCL18), and angiogenesis (eg, vascular endothelial growth factor) are elevated in the CSF of patients with NM. Evidence that some tumor types are more likely to infiltrate the CNS also has stimulated research into primary tumor markers predictive of CNS metastases. At present, there is no tumor marker or patient characteristic that reliably predicts the development of NM, and diagnosis still relies on suggestive signs and symptoms, positive CSF cytology, or a consistent MRI-all late manifestations of NM. Until techniques capable of detecting NM early are developed, increased awareness of the disease and standardized evaluation are likely to have the greatest impact on improving diagnosis and implementing earlier treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19660682     DOI: 10.1053/j.seminoncol.2009.05.005

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  63 in total

Review 1.  Neurologic complications of cancer and its treatment.

Authors:  Pierre Giglio; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2010-01       Impact factor: 5.075

2.  Safety of intra-cerebrospinal fluid chemotherapy in onco-haematological patients: a retrospective analysis of 627 interventions.

Authors:  Javier Pardo-Moreno; Cristina Fernández; Rafael Arroyo; Carlos Ruiz-Ocaña; Concepción Aláez; María-Luz Cuadrado
Journal:  J Neurooncol       Date:  2015-09-05       Impact factor: 4.130

3.  Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.

Authors:  Stephanie Heon; Beow Y Yeap; Gregory J Britt; Daniel B Costa; Michael S Rabin; David M Jackman; Bruce E Johnson
Journal:  Clin Cancer Res       Date:  2010-10-28       Impact factor: 12.531

4.  Leptomeningeal metastasis from solid tumors: a diagnostic and therapeutic challenge.

Authors:  Maria Grazia Passarin; Teodoro Sava; Jenny Furlanetto; Annamaria Molino; Rolando Nortilli; Anna Maria Musso; Marta Zaninelli; Tiziano Franceschi; Daniele Orrico; Sabrina Marangoni; Cristina Dealis; Claudio Graiff; Rodella Filippo; Salvatore Grisanti; Edda Simoncini; Lucia Vassalli; Alfredo Berruti; Rebecca Pedersini
Journal:  Neurol Sci       Date:  2014-07-16       Impact factor: 3.307

5.  Meningeal melanocytosis: a possibly useful treatment for a rare primary brain neoplasm.

Authors:  Júlia Miró; Roser Velasco; Carles Majós; Miguel Gil; Susana Boluda; Jordi Bruna
Journal:  J Neurol       Date:  2011-01-20       Impact factor: 4.849

6.  Leptomeningeal metastases.

Authors:  Jordi Bruna; Marta Simó; Roser Velasco
Journal:  Curr Treat Options Neurol       Date:  2012-08       Impact factor: 3.598

7.  A rare magnetic resonance imaging pattern of leptomeningeal carcinomatosis: a case description.

Authors:  Chang Liu; Yu Zhang; Yi Li; Hui Bu; Zhaohua Meng; Yingxiao Ji; Jiang Wu; Yueli Zou; Xinxin Chen; Junying He; Kun Hong
Journal:  Quant Imaging Med Surg       Date:  2021-07

8.  A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancer.

Authors:  E Le Rhun; S Taillibert; F Zairi; N Kotecki; P Devos; A Mailliez; V Servent; L Vanlemmens; P Vennin; T Boulanger; M C Baranzelli; C André; G Marliot; J L Cazin; F Dubois; R Assaker; J Bonneterre; M C Chamberlain
Journal:  J Neurooncol       Date:  2013-03-01       Impact factor: 4.130

9.  CSF CA 15-3 in breast cancer-related leptomeningeal metastases.

Authors:  Emilie Le Rhun; Andrew Kramar; Sophie Salingue; Marie Girot; Isabelle Rodrigues; Audrey Mailliez; Fahed Zairi; Edgar Bakhache; Yves Marie Robin; Sophie Taillibert; François Dubois; Jacques Bonneterre; Marc C Chamberlain
Journal:  J Neurooncol       Date:  2014-01-28       Impact factor: 4.130

10.  Diagnostic criteria for pediatric multiple sclerosis.

Authors:  Jennifer P Rubin; Nancy L Kuntz
Journal:  Curr Neurol Neurosci Rep       Date:  2013-06       Impact factor: 5.081

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.